期刊文献+

p21^(WAF1/CIP1)和PCNA在骨肉瘤中的表达及对预后的评价 被引量:3

p21WAF1/CIP1 and PCNA expressions in human osteosarcoma and their values to assess the prognosis of the patient
下载PDF
导出
摘要 目的:探讨p21(WAF1/CIP1)基因mRNA及p21WAF1蛋白、PCNA(增殖细胞核抗原)与骨肉瘤的发生、发展之间的关系及其对预后的评价。方法:采用原位杂交及免疫组化法(LSAB法)检测p21(WAF1/CIP1)基因mRNA及p21WAF1蛋白、PCNA在骨肉瘤中的表达。结果:原位杂交结果显示,p21(WAF1/CIP1)mRNA在45例骨肉瘤中有19例阳性表达,阳性率为42%;在10例骨纤维结构不良中有8例阳性表达,阳性率为80%。免疫组化结果显示,p21(WAF1)蛋白在45例骨肉瘤中有8例阳性表达,阳性率为17.7%;在10例骨纤维结构不良有5例阳性表达,阳性率为50%。PCNA在45例骨肉瘤中均有表达,阳性率为100%。p21(WAF1/CIP1)mRNA表达阳性者术后生存时间与p21(WAF1/CIP1)mRNA表达阴性者术后生存时间之间的差异有显著性(P<0.05)。结论:①随着骨肿瘤恶性度的升高,p21(WAF1/CIP1)mRNA及p21WAF1蛋白的表达下降;②p21(WAF1/CIP1)mRNA及p21WAF1蛋白表达的数量和水平的下降是导致人类骨组织发生恶性骨肿瘤的可能原因之一;③随访结果显示,p21(WAF1/CIP1)mRNA在骨肉瘤中的表达对预后有影响。 Objective: To investigate the expressions of protein p21WAF1/CIP1 and PCNA in human osteosarcoma, and their relationships to the development and progress of osteosarcoma the assess of their prognosis of the patient. Methods: The expressions at mRNA level and protein level for p21WAF1/CIP1 and PCNA were determined in 45 cases of osteosarcoma by using in stita hybridization and immunohistochemical techniques respectively. Results: The positive rate of p21WAF1/CIP1 at mRNA level in osteosarcoma and fibro osseous dysplasia was 42% and 80% respectively (P< 0.05). The positive rate of p21WAF1 protein between osteosarcoma and fibro osseous dysplasia ( 17.7% and 50% respectively) was also significantly different(P< 0.05) . while positive rate of PCNA was 100% . There was significant difference of survival time after operation between patient with p21WAF1/CIP1 mRNA positive expression and that with p21WAF1/CIP1 mRNA negative expression(P< 0.05). Conclusions: ① Along with increase of malignancy the expressions of p21WAF1/CIP1 mRNA and p21WAF1 protein in bone tumor tend to decrease; ② The decrease of p21WAF1/CIP1 mRNA and p21WAF1 protein expression may be one of the causes induceing maligant tumor in bone;③ The follow up resuts indicate that the exression of p21WAF1/CIP1 mRNA in osteosarcoma can influence the prognosis of osteosarcoma patients.
出处 《癌症》 SCIE CAS CSCD 北大核心 2000年第9期850-855,共6页 Chinese Journal of Cancer
基金 本课题受卫生部科学研究基金项目!(96-1-121)
关键词 骨肉瘤 P21^WAF1/CIP1 PCNA 原位杂交 免疫组化 Osteosarcoma p21WAF1/CIP1 PCNA In situ hybridization Immunohistochemistry
  • 相关文献

参考文献7

二级参考文献2

  • 1Zhang W,Cancer Res,1995年,55卷,668页
  • 2Xiong Y,Nature,1993年,366卷,701页

共引文献11

同被引文献57

  • 1陈志伟,吴苏稼.骨肉瘤组织中HER2、P-糖蛋白的表达与预后的关系[J].医学研究生学报,2005,18(5):462-464. 被引量:10
  • 2[4]Ferrari S,Bertoni F,Zanella L,et al.Evaluation of P-glycoprotein,HER-2/ErbB-2,p53 and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.Cancer,2004,100:1936-1942.
  • 3[5]Honoki K,Tsujiuchi T.Possible involvement of bcl-2 suppression in wildtype p53 gene-dependent cell growth repression in rat osteosarcoma cells.Toxicol Pathol,2000,28:575-579.
  • 4[6]Hanada M,Aime-Sempe C,Sato T,et al.Structure-function analysis of Bcl-2 protein.J Biol Cbem,1995,270:11962.
  • 5[7]Moalic-Juge S,Liagre B,Dural R,et al.The anti-apoptotie property of NS-398 at high-dose can be mediated in part through NF-kappa B activation,hsp-70 induction and a decrease in caspase-3 activity in human osteosarcoma cells.Int J Oncol,2002,20:1255-1262.
  • 6[9]Porter PL,Gown AM,Kromp SG,et al.Widespread p53 overexpression in human malignant.Am J Pathol,1992,140:145-148.
  • 7[10]Radig K,Schneider-Stock R,Haeckl C,et al.P53 gene mutations in osteosarcoma of low-grade malignancy.Hum Pathol,1998,29:1310-1316.
  • 8[11]Tsang WP,Chan SP,Fung KP,et al.Modulation ofmultidrug resistanceassociated protein-1(MRPI)by p53 mutant in SaoS-2 cells.Cancer Chemother Pharmacol,2003,51:161-166.
  • 9[12]Hellwinkel OJ,Muller J,Pollmann A,et al.Osteosarcoma cell lines display variable individual eactions on wildtype p53 and Rb tumor-suppressor transgenes.J Gene Med,2004,11:542-549.
  • 10[13]Densmore CL,Kleinerman ES,Gautam A,et al.Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes.Cancer Gene Ther,2001,8:619-627.

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部